PBL
MCID: PLS025
MIFTS: 48

Plasmablastic Lymphoma (PBL)

Categories: Blood diseases, Cancer diseases, Gastrointestinal diseases, Immune diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Plasmablastic Lymphoma

MalaCards integrated aliases for Plasmablastic Lymphoma:

Name: Plasmablastic Lymphoma 11 19 58 14 71 75 33
Immunoblastic Large-Cell Lymphoma 71
Pbl 58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:0080779
NCIt 49 C7224
ICD10 via Orphanet 32 C83.3
UMLS via Orphanet 72 C3472614
Orphanet 58 ORPHA289666
ICD11 33 803046659
UMLS 71 C0079746 C3472614

Summaries for Plasmablastic Lymphoma

Orphanet: 58 A rare aggressive B-cell non-Hodgkin lymphoma characterized by neoplastic cells resembling B immunoblasts or plasmablasts with a CD20-negative plasmacytic phenotype. The tumor may occur in the oral cavity, the gastrointestinal tract, or other, predominantly extranodal, sites and is typically associated with immunodeficiency or -suppression. The tumor cells are EBV-positive in most cases. Patients often present with disseminated bone involvement. Paraproteinemia may also be detected. Prognosis is generally poor.

MalaCards based summary: Plasmablastic Lymphoma, also known as immunoblastic large-cell lymphoma, is related to lymphoma aids related and b-cell non-hodgkin lymphoma. An important gene associated with Plasmablastic Lymphoma is MYC (MYC Proto-Oncogene, BHLH Transcription Factor), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Iodine and Aldesleukin have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and skin, and related phenotypes are homeostasis/metabolism and neoplasm

GARD: 19 Plasmablastic lymphoma is an aggressive form of non-Hodgkin lymphoma. Although the condition most commonly occurs in the oral cavity, it can be diagnosed in many other parts of the body such as the gastrointestinal tract, lymph nodes, and skin. The exact underlying cause of Plasmablastic lymphoma is poorly understood; however, it is often associated with suppression of the immune system (i.e. HIV infection, immunosuppressive therapy).

Disease Ontology: 11 A diffuse large B-cell lymphoma that is characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells.

Wikipedia: 75 Plasmablastic lymphoma (PBL) is a type of large B-cell lymphoma recognized by the World Health... more...

Related Diseases for Plasmablastic Lymphoma

Diseases related to Plasmablastic Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 408)
# Related Disease Score Top Affiliating Genes
1 lymphoma aids related 30.9 MYC BCL6
2 b-cell non-hodgkin lymphoma 30.9 PRDM1 BCL6
3 acquired immunodeficiency syndrome 30.8 MYC CD79A CD38 BCL6
4 lymphoproliferative syndrome 30.5 TNFRSF8 STAT3 JAK1 BCL6
5 immune deficiency disease 30.3 VDR TNFRSF8 PDCD1 CD79A CD38 BCL6
6 cheilitis 30.2 STAT3 PDCD1 CD274
7 lymphoma, hodgkin, classic 30.2 TNFRSF8 STAT3 SOCS1 PAX5 IRF4 BCL6
8 essential thrombocythemia 30.0 STAT3 SOCS1 MYC JAK1
9 anaplastic large cell lymphoma 29.9 TNFRSF8 STAT3 PAX5
10 gallbladder lymphoma 29.9 MME BCL6
11 autoimmune disease 29.9 VDR STAT3 PDCD1 CD79A CD274
12 burkitt lymphoma 29.8 TNFRSF8 STAT3 PRDM1 PAX5 MYC MME
13 acute biphenotypic leukemia 29.8 PAX5 MME CD79A
14 lymphoma 29.7 TNFRSF8 STAT3 PRDM1 PDCD1 PAX5 MYC
15 primary central nervous system lymphoma 29.7 PAX5 BCL6
16 adult t-cell leukemia/lymphoma 29.6 TNFRSF8 MYC IRF4
17 plasmacytoma 29.6 PRDM1 PAX5 MYC IRF4 CD79A CD38
18 richter's syndrome 29.6 PAX5 MYC IGHV4-38-2 CD38 BCL6
19 severe combined immunodeficiency 29.6 TNFRSF8 STAT3 JAK1 CD38
20 reticulosarcoma 29.5 TNFRSF8 PAX5 MYC CD79A BCL6
21 vaginal cancer 29.5 MME CD274
22 rhabdomyosarcoma 29.5 STAT3 PAX5 MYC MME CD274
23 plasma cell neoplasm 29.5 SDC1 PAX5 MYC IGHV4-38-2 CD79A CD38
24 peripheral nervous system disease 29.4 TNFRSF8 STAT3 MYC MME CD274
25 b-cell lymphoma 29.4 TNFRSF8 STAT3 SOCS1 PRDM1 PAX5 MYC
26 b-lymphoblastic leukemia/lymphoma 29.4 PAX5 MYC MME IGHV4-38-2
27 small intestine lymphoma 29.3 TNFRSF8 MME CD79A BCL6
28 leukemia, chronic myeloid 29.3 STAT3 SOCS1 MYC IRF4 CD38
29 peripheral t-cell lymphoma 29.1 TNFRSF8 STAT3 PAX5 MME BCL6
30 follicular lymphoma 29.1 STAT3 PAX5 MYC MME IRF4 BCL6
31 skin disease 29.0 VDR TNFRSF8 STAT3 PDCD1 MYC JAK1
32 diffuse large b-cell lymphoma 29.0 TNFRSF8 PRDM1 PAX5 MYC MME IRF4
33 t-cell acute lymphoblastic leukemia 28.8 TNFRSF8 STAT3 MYC IRF4
34 waldenstroem's macroglobulinemia 28.8 SDC1 PAX5 IRF4 IGHV4-38-2 CD38
35 gastric lymphoma 28.8 TNFRSF8 MME IRF4 IGHV4-38-2 CD79A BCL6
36 bone lymphoma 28.7 TNFRSF8 PAX5 MME IRF4 CD79A BCL6
37 composite lymphoma 28.6 TNFRSF8 PAX5 MME IGHV4-38-2 CD79A CD274
38 multicentric castleman disease 28.6 TNFRSF8 SDC1 PAX5 IRF4 CD79A CD38
39 myeloma, multiple 28.6 TNFRSF8 STAT3 SDC1 PRDM1 PAX5 MYC
40 lymphatic system disease 28.6 TNFRSF8 MYC MME IRF4 IGHV4-38-2 BCL6
41 breast lymphoma 28.4 TNFRSF8 PAX5 MME IRF4 CD79A BCL6
42 chronic lymphocytic leukemia/small lymphocytic lymphoma 28.3 TNFRSF8 PAX5 MME IGHV4-38-2 CD79A CD38
43 angioimmunoblastic t-cell lymphoma 28.2 TNFRSF8 PAX5 MME IRF4 IGHV4-38-2 BCL6
44 extramedullary plasmacytoma 28.2 SDC1 PAX5 MME IRF4 IGHV4-38-2 CD79A
45 mature t-cell and nk-cell lymphoma 28.1 TNFRSF8 STAT3 PAX5 MYC MME IGHV4-38-2
46 lymphoma, non-hodgkin, familial 28.0 TNFRSF8 STAT3 SOCS1 SDC1 PAX5 MYC
47 testicular lymphoma 27.9 TNFRSF8 PDCD1 MME IRF4 IGHV4-38-2 CD79A
48 leukemia, acute lymphoblastic 27.9 PAX5 MYC MME JAK1 IRF4 IGHV4-38-2
49 central nervous system lymphoma 27.6 TNFRSF8 PAX5 MYC MME IRF4 IGHV4-38-2
50 lymphoma, mucosa-associated lymphoid type 27.6 TNFRSF8 SDC1 PAX5 MYC MME IRF4

Graphical network of the top 20 diseases related to Plasmablastic Lymphoma:



Diseases related to Plasmablastic Lymphoma

Symptoms & Phenotypes for Plasmablastic Lymphoma

MGI Mouse Phenotypes related to Plasmablastic Lymphoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.24 BCL6 CD274 CD38 CD79A IRF4 JAK1
2 neoplasm MP:0002006 10.13 CD79A IRF4 MYC PAX5 PDCD1 PRDM1
3 endocrine/exocrine gland MP:0005379 10.1 BCL6 CD38 IRF4 JAK1 MYC PDCD1
4 cellular MP:0005384 10.1 BCL6 CD274 CD38 CD79A IRF4 MME
5 immune system MP:0005387 10.09 BCL6 CD274 CD38 CD79A IRF4 JAK1
6 normal MP:0002873 10.06 BCL6 CD79A JAK1 MYC PAX5 PRDM1
7 liver/biliary system MP:0005370 10.06 BCL6 CD79A JAK1 MME MYC PDCD1
8 muscle MP:0005369 9.98 BCL6 MYC PDCD1 PRDM1 SOCS1 STAT3
9 hematopoietic system MP:0005397 9.86 BCL6 CD274 CD38 CD79A IRF4 JAK1
10 integument MP:0010771 9.28 BCL6 CD274 JAK1 MME MYC SDC1

Drugs & Therapeutics for Plasmablastic Lymphoma

Drugs for Plasmablastic Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Aldesleukin Approved Phase 3 110942-02-4
3
Cadexomer iodine Experimental Phase 3 94820-09-4
4 Anti-HIV Agents Phase 3
5 Anti-Retroviral Agents Phase 3
6 Tositumomab I-131 Phase 3
7 Interleukin-2 Phase 3
8 Analgesics, Non-Narcotic Phase 3
9 Analgesics Phase 3
10
Vorinostat Approved, Investigational Phase 1, Phase 2 149647-78-9 5311
11
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
12
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
13
Ondansetron Approved Phase 2 99614-02-5 4595
14
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
15
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
16
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
17
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
18
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
19
Gemcitabine Approved Phase 2 95058-81-4, 122111-03-9 60750
20
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239
21
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
22
Alemtuzumab Approved, Investigational Phase 2 216503-57-0
23
Rasburicase Approved, Investigational Phase 2 134774-45-1
24
Topotecan Approved, Investigational Phase 2 123948-87-8, 119413-54-6 60699 60700
25
Mitoxantrone Approved, Investigational Phase 2 70476-82-3, 65271-80-9 4212
26
Lomustine Approved, Investigational Phase 2 13010-47-4 3950
27
Procarbazine Approved, Investigational Phase 2 671-16-9 4915
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
29
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
30
Daratumumab Approved Phase 2 945721-28-8
31
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
32
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704
33
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
34
Picropodophyllin Approved, Investigational Phase 1, Phase 2 518-28-5, 477-47-4 10607 72435
35
Vincristine Approved, Investigational Phase 1, Phase 2 2068-78-2, 57-22-7 5978
36
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
37
Nivolumab Approved Phase 2 946414-94-4
38
Sodium citrate Approved, Investigational Phase 1, Phase 2 68-04-2 23431961
39
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 3640 5754
40
Ixazomib Approved, Investigational Phase 1, Phase 2 1072833-77-2 25183872
41
Hydrocortisone succinate Approved Phase 1, Phase 2 2203-97-6 3643
42
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
43
Busulfan Approved, Investigational Phase 2 55-98-1 2478
44
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
45
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
46
Iron Approved Phase 2 7439-89-6 29936
47
Deferasirox Approved, Investigational Phase 2 201530-41-8 214348 5493381
48
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
49
Ifosfamide Approved Phase 2 3778-73-2 3690
50
Ipilimumab Approved Phase 1, Phase 2 477202-00-9

Interventional clinical trials:

(show top 50) (show all 124)
# Name Status NCT ID Phase Drugs
1 INSPIRE: An Internet-based RCT for Long-term Survivors of Hematopoietic Stem Cell Transplantation Completed NCT00799461 Phase 3
2 Phase III Rituxan/BEAM vs. Bexxar/BEAM With Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Persistent or Relapsed Chemotherapy Sensitive Diffuse Large B-cell Non-Hodgkin's Lymphoma (BMTCTN0401) Completed NCT00329030 Phase 3 Autologous transplantation using rituxan/BEAM;Autologous transplantation using Bexxar/BEAM
3 Total Body Irradiation, Etoposide, Cyclophosphamide and Autologous Peripheral Blood Stem Cell Transplantation Followed by Randomization to Therapy With Interleukin-2 Versus Observation for Patients With Non-Hodgkin's Lymphoma Completed NCT00002649 Phase 3 cyclophosphamide;etoposide
4 A Sequential Phase I/Randomized Phase II Trial of Vorinostat and Risk-Adapted Chemotherapy With Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma Completed NCT01193842 Phase 1, Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate;Vorinostat
5 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
6 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
7 A Phase I/II Study of Cellular Immunotherapy With Donor Central Memory-derived Virus-specific CD8+ T-cells Engineered to Target CD19 for CD19+ Malignancies After Allogeneic Hematopoietic Stem Cell Transplant Completed NCT01475058 Phase 1, Phase 2
8 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
9 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
10 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
11 A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma Completed NCT00049036 Phase 2 etoposide;doxorubicin hydrochloride;vincristine sulfate;prednisone;cyclophosphamide
12 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
13 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
14 A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma Completed NCT00131937 Phase 2 sorafenib tosylate
15 A Phase II Trial Evaluating The Efficacy of Radioiodinated Tositumomab (Anti-CD20) Antibody, Etoposide and Cyclophosphamide Followed by Autologous Transplantation, for Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00073918 Phase 2 cyclophosphamide;etoposide
16 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
17 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
18 A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor G-CSF Mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies A Multi-Center Trial Completed NCT00105001 Phase 2 Fludarabine Phosphate;Tacrolimus;Mycophenolate Mofetil;Sirolimus
19 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
20 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
21 A Phase II Study of Oxaliplatin in Relapsed and Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2 oxaliplatin
22 A Phase II Study of Recombinant Human Interleukin-12 (rhIL-12) for the Treatment of Relapsed Lymphoma and Hodgkin's Disease Completed NCT00003210 Phase 2
23 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
24 A Pilot Study To Determine The Toxicity Of The Addition Of Rituximab To The Induction And Consolidation Phases And The Addition Of Rasburicase To The Reduction Phase In Children With Newly Diagnosed Advanced B-Cell Leukemia/Lymphoma Treated With LMB/FAB Therapy Completed NCT00057811 Phase 2 doxorubicin hydrochloride;cyclophosphamide;methotrexate;rasburicase;leucovorin calcium;prednisone;methylprednisolone;cytarabine;etoposide;vincristine sulfate;hydrocortisone sodium succinate
25 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
26 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
27 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
28 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
29 A Phase II Study of CCI-779 in B-cell Lymphoma and CLL Completed NCT00290472 Phase 2 temsirolimus
30 A Phase II Study of Intrathecal Topotecan (NSC #609699) in Patients With Refractory Meningeal Malignancies Completed NCT00005811 Phase 2 topotecan hydrochloride
31 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
32 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
33 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
34 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
35 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
36 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
37 Phase II Study of Novantrone(R) (Mitoxantrone) and Etoposide in Patients With HIV Associated Large Cell and Immunoblastic Lymphomas Completed NCT00002003 Phase 2 Mitoxantrone hydrochloride;Etoposide
38 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
39 Randomized, Phase II Trial of CHOP vs. Oral Chemotherapy With Concomitant Antiretroviral Therapy in Patients With HIV-Associated Lymphoma in Sub-Saharan Africa Completed NCT01775475 Phase 2 cyclophosphamide;doxorubicin hydrochloride;vincristine sulfate;prednisone;lomustine;etoposide;procarbazine hydrochloride
40 A Multicenter Phase 2 Study of Belantamab Mafodotin in Relapsed or Refractory Plasmablastic Lymphoma and ALK+ Large B-cell Lymphoma Recruiting NCT04676360 Phase 2 Belantamab Mafodotin
41 An Open Label, Phase 2 Study to Evaluate Activity and Safety of Daratumumab in Combination With Bortezomib and Dexamethasone in Patients With Relapsed or Refractory Plasmablastic Lymphoma (DALYA Trial) Recruiting NCT04915248 Phase 2 Daratumumab;Bortezomib;Dexamethasone
42 A Phase I Study of Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-Selected CD34+ Cells Recruiting NCT02797470 Phase 1, Phase 2 Carmustine;Cytarabine;Etoposide;Melphalan
43 A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2 Fludarabine phosphate;Thiotepa;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
44 Phase II Study of Dose-Adjusted EPOCH+/-Rituximab in Adults With Untreated Burkitt Lymphoma, c-MYC Positive Diffuse Large B-Cell Lymphoma and Plasmablastic Lymphoma Active, not recruiting NCT01092182 Phase 2 EPOCH-R;EPOCH-RR
45 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Active, not recruiting NCT03038672 Phase 2 Varlilumab
46 A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients With MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen Active, not recruiting NCT02481310 Phase 1, Phase 2 Cyclophosphamide;Cytarabine;Doxorubicin Hydrochloride;Etoposide;Ixazomib Citrate;Methotrexate;Prednisone;Therapeutic Hydrocortisone;Vincristine Sulfate
47 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Active, not recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
48 A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL/SLL/PLL or NHL With Lenalidomide Alone or With Rituximab Terminated NCT01419795 Phase 2 lenalidomide
49 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
50 RITUXIMAB FOR PREVENTION OF ACUTE GRAFT-VERSUS-HOST DISEASE (GVHD) AFTER UNRELATED DONOR ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) Terminated NCT01044745 Phase 2 rituximab;mycophenolate mofetil;tacrolimus;anti-thymocyte globulin;cyclophosphamide;fludarabine phosphate;busulfan

Search NIH Clinical Center for Plasmablastic Lymphoma

Genetic Tests for Plasmablastic Lymphoma

Anatomical Context for Plasmablastic Lymphoma

Organs/tissues related to Plasmablastic Lymphoma:

MalaCards : B Cells, Bone, Skin, T Cells, Bone Marrow, Liver, Myeloid

Publications for Plasmablastic Lymphoma

Articles related to Plasmablastic Lymphoma:

(show top 50) (show all 693)
# Title Authors PMID Year
1
Clinicopathological characteristics and long-term outcomes of plasmablastic lymphoma in British Columbia. 62
35961783 2022
2
Clinicopathologic and Molecular Characterization of Epstein-Barr Virus-positive Plasmacytoma. 62
35650679 2022
3
Plasmablastic lymphoma masked by hidradentitis suppurativa. 62
35990238 2022
4
CD138- Plasmablastic Lymphoma. 62
36161544 2022
5
HIV-associated plasmablastic lymphoma: A single-centre 12-year experience in Kwa-Zulu Natal, South Africa. 62
35229978 2022
6
Primary central nervous system other iatrogenic immunodeficiency-associated lymphoproliferative disorders presenting as extraosseous plasmacytoma with a progressive clinical course: A case report and literature review. 62
36065518 2022
7
Plasmablastic lymphoma: An update. 62
36074710 2022
8
High expression of HIV-1 matrix protein p17 in both lymphoma and lymph node tissues of AIDS patients. 62
35939971 2022
9
Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. 62
36013165 2022
10
Human Immunodeficiency Virus Associated Plasmablastic Lymphoma Involving Bones and Peritoneum in a 4-Year-old Child. 62
35973102 2022
11
Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma. 62
35657404 2022
12
Plasmablastic lymphoma with MYC::IGH fusion and BCL2 rearrangement. 62
36051039 2022
13
Plasmablastic lymphoma with aberrant expression of CD3 and CD4. 62
35060329 2022
14
Bortezomib, Lenalidomide and Dexamethasone Combination Induced Complete Remission in Relapsed/Refractory Plasmablastic Lymphoma: Case Report of a Potential Novel Treatment Approach. 62
35877259 2022
15
Unilateral Maxillary Sinus Plasmablastic Lymphoma in an Immunocompetent Patient. An Unusual Occurrence Report and Literature Review. 62
33044847 2022
16
Unusual bilateral kidney and duodenal plasmablastic lymphoma presentation in an elderly patient: A case report. 62
35761897 2022
17
Daratumumab with ifosfamide, carboplatin and etoposide for the treatment of relapsed plasmablastic lymphoma. 62
35506301 2022
18
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. 62
35472248 2022
19
Unexpected plasmablastic lymphoma in a young adult with unknown HIV infection: case report. 62
35837199 2022
20
Plasmablastic lymphoma of the colon in HIV negative patient; a case report with literature review. 62
35600199 2022
21
Relapse of Plasmablastic Lymphoma With Cutaneous Involvement in an Immunocompetent Male. 62
32955361 2022
22
CD3-and CD20-negative extramedullary non-Hodgkin leukemia/lymphoma: a histopathological study of 118 cases. 62
35307403 2022
23
Plasmablastic Lymphoma Presenting With Rectosigmoid Perforation in a Human Immunodeficiency Virus-Positive Patient. 62
35706759 2022
24
Epstein-Barr virus-positive mucocutaneous ulcer, plasmablastic type, associated with nodal CD4+ angioimmunoblastic T-cell lymphoma and generalised pruritus: a self-limiting lymphoproliferative disorder resembling cutaneous plasmablastic lymphoma. 62
35523507 2022
25
Lymphoproliferative Neoplasms With Plasmablastic Morphology. 62
34559873 2022
26
Ileal plasmablastic lymphoma presenting as intestinal occlusion in an HIV-negative patient with chronic lymphocytic leukemia. 62
34933564 2022
27
Cutaneous Involvement in Diseases with Plasma Cell Differentiation: Diagnostic Approach. 62
35621636 2022
28
HIV-related non-Hodgkin lymphomas affecting the oral cavity: a clinicopathologic study of 11 cases. 62
34874927 2022
29
Epstein-Barr virus prevalence among subtypes of malignant lymphoma in Rwanda, 2012 to 2018. 62
34626122 2022
30
HIV-related plasmablastic lymphoma causing extensive bone destruction in the mandible. 62
35151011 2022
31
A Rare Case of Plasmablastic Lymphoma in a Patient with HIV and SARS-CoV-2 Infections. 62
35323329 2022
32
Plasmablastic lymphoma of the rectum: case report of a rare location and literature review. 62
35186254 2022
33
Oral versus extra-oral plasmablastic lymphoma: A comparative analysis of 101 cases. 62
34910327 2022
34
Hematologic cancers in individuals infected by HIV. 62
34469512 2022
35
Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. 62
34332791 2022
36
Plasmablastic lymphomas show restricted EBV latency profile and MYC gene aberrations. 62
34612761 2022
37
Tumor Thrombus on 18F-FDG PET/CT in Stage IV Plasmablastic Lymphoma. 62
34284479 2022
38
Sinonasal Plasmablastic Lymphoma Arising in the Setting of Recurrent Nasal Polyposis in an Immunocompetent Individual. 62
35001641 2022
39
Transient atypical lymphoplasmacytic proliferation of the endometrium associated with pyometra: a case report. 62
35949809 2022
40
Primary adrenal plasmablastic lymphoma presenting as lymphomatous meningitis - A diagnostic perplexity. 62
34464483 2022
41
Spontaneous Regression of Plasmablastic Lymphoma in an Immunocompetent Patient: Case Report and Review of the Literature. 62
35677531 2022
42
Post-transplant Lymphoproliferative Disorder Presenting as Breast Nodule and Intestinal Obstruction in a Renal Transplant Recipient: A Case Report. 62
35000776 2022
43
Plasmablastic Lymphoma Presenting as Extensive Peritoneal and Retroperitoneal Nodules in an HIV-Positive Patient. 62
35073776 2022
44
Plasmablastic Lymphoma Mimicking Osteomyelitis of Femur in an Immunocompetent Individual: A Case Report. 62
35165629 2022
45
[Plasmablastic myeloma initially presented with ascites]. 62
35387932 2022
46
[Endoscopic mucosal resection of localized plasmablastic lymphoma with early rectal cancer:a rare case report and literature review]. 62
35264486 2022
47
Tibial Plasmablastic Lymphoma in a HIV-Negative Child: A Novel Extraoral Localisation. 62
35721803 2022
48
Phenogenomic heterogeneity of post-transplant plasmablastic lymphomas. 62
33297669 2022
49
Integrative genomic and transcriptomic analysis in plasmablastic lymphoma identifies disruption of key regulatory pathways. 62
34714908 2022
50
Successful treatment of refractory retroperitoneal Epstein-Barr virus-positive diffuse large B-cell lymphoma with secondary hemophagocytic syndrome by sequential combination regimen of PD-1 blockade and chimeric antigen receptor T cells: a case report. 62
34387604 2022

Variations for Plasmablastic Lymphoma

Expression for Plasmablastic Lymphoma

Search GEO for disease gene expression data for Plasmablastic Lymphoma.

Pathways for Plasmablastic Lymphoma

Pathways related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

(show all 35)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 BCL6 CD274 CD79A IRF4 JAK1 MME
2
Show member pathways
13.14 TNFRSF8 STAT3 SOCS1 SDC1 MYC JAK1
3 12.73 CD274 MYC PRDM1 SOCS1 STAT3
4
Show member pathways
12.54 STAT3 SOCS1 MYC JAK1 IRF4
5 12.1 VDR PRDM1 MYC IRF4 BCL6
6
Show member pathways
12.07 STAT3 MYC JAK1
7 11.95 VDR PRDM1 BCL6
8 11.92 TNFRSF8 STAT3 SOCS1 PRDM1 PDCD1 PAX5
9
Show member pathways
11.89 STAT3 SOCS1 MYC
10
Show member pathways
11.89 JAK1 MYC SOCS1 STAT3
11 11.86 SDC1 MME CD79A CD38
12 11.82 PDCD1 JAK1 CD79A
13
Show member pathways
11.78 STAT3 JAK1 IRF4
14 11.67 STAT3 SOCS1 JAK1
15 11.67 STAT3 SOCS1 MYC JAK1 IRF4 BCL6
16 11.66 MME IRF4 CD38
17 11.62 STAT3 JAK1 IRF4
18 11.57 STAT3 SOCS1 JAK1
19
Show member pathways
11.52 STAT3 MYC JAK1
20
Show member pathways
11.51 STAT3 SOCS1 JAK1
21 11.5 STAT3 MYC JAK1
22 11.48 SOCS1 JAK1 IRF4 BCL6
23 11.41 STAT3 MYC JAK1
24 11.35 STAT3 SOCS1 PDCD1 CD274
25 11.35 SLAMF7 PRDM1 PDCD1 PAX5 IRF4 CD79A
26 11.31 SOCS1 JAK1 IRF4
27 11.29 STAT3 SOCS1 JAK1
28 11.27 STAT3 MYC JAK1
29 11.22 STAT3 PAX5 IRF4
30 11.19 STAT3 SOCS1 JAK1
31
Show member pathways
11.19 STAT3 PRDM1 MYC CD274
32 11.01 STAT3 PDCD1 CD274
33 10.92 STAT3 JAK1
34 10.76 STAT3 IRF4
35 10.63 STAT3 MYC

GO Terms for Plasmablastic Lymphoma

Cellular components related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.36 SLAMF7 SDC1 PDCD1 IGHV4-38-2 CD79A CD274

Biological processes related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell proliferation GO:0042100 9.73 CD79A CD38 BCL6
2 growth hormone receptor signaling pathway via JAK-STAT GO:0060397 9.67 STAT3 JAK1
3 receptor signaling pathway via JAK-STAT GO:0007259 9.63 STAT3 SOCS1 JAK1
4 T-helper 17 cell lineage commitment GO:0072540 9.62 STAT3 IRF4
5 positive regulation of interleukin-10 production GO:0032733 9.43 STAT3 IRF4 CD274
6 immune system process GO:0002376 9.23 SLAMF7 PRDM1 PDCD1 IRF4 CD79A CD274

Molecular functions related to Plasmablastic Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.5 VDR STAT3 PRDM1 IRF4 BCL6
2 DNA-binding transcription factor activity GO:0003700 9.44 VDR STAT3 PRDM1 PAX5 MYC IRF4

Sources for Plasmablastic Lymphoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....